June 12 (Reuters) - VolitionRX Ltd VNRX.A:
VOLITION ANNOUNCES MARS CONSORTIUM CLINICAL STUDY SUGGESTS NU.Q® H3.1. CONCENTRATIONS ARE CLOSELY ASSOCIATED WITH SEPSIS AND ORGAN FAILURE
Source text: ID:nPnblsMN5a
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))